Study of B/F/TAF in Participants Switching From CAB + RPV to B/F/TAF for HIV-1 Infection (EMPOWER)

Key Inclusion Criteria:

• People with HIV-1 (PWH) or provider decision to switch off CAB+RPV IM injections dueto intolerance, inconvenience, adverse events (AEs), or willing to switch to (andintention to remain on) daily B/F/TAF

• Currently virologically suppressed (HIV-1 RNA < 50 copies/mL) on CAB+RPV IMinjections every 2 months

• Currently on CAB+RPV IM injections every 2 months and received at least one dose ofCAB+RPV IM injection; no missed CAB+RPV injections

• Ability to receive B/F/TAF up to 7 days prior to the next scheduled dose of CAB+RPV

• Documented plasma HIV-1 RNA < 50 copies/mL during treatment for ≥ 6 months precedingthe screening visit

• No documented or suspected resistance to BIC, emtricitabine (FTC), or tenofovir (TFV).

Key Exclusion Criteria:

• History of B/F/TAF intolerance

• History of previous INSTI virologic failure including CAB+RPV

• Requirement for ongoing therapy with any prohibited medications listed in localprescribing information for B/F/TAF starting within 30 days prior to screening until 30 days following the last dose of study drug

• Have been treated within 3 months of study screening or expected to receive duringthe study immunosuppressant therapies or chemotherapeutic agents (eg, chronic (atleast 4 weeks) systemic steroids, immunoglobulins, and other immune- orcytokine-based therapies)

• Need for oral antiretroviral therapy (ART) bridge or use of other antiretroviral (ARV) agents prior to starting B/F/TAF on Day 1

Note: Other protocol defined Inclusion/Exclusion criteria may apply.